Piflufolastat
Piflufolastat is a small molecule ligand targeting prostate-specific membrane antigen (PSMA) that is used as a radiotracer for PET imaging in prostate cancer and is under investigation for targeted radiotherapy applications in breast and pancreatic cancer. It binds with high affinity to PSMA, enabling highly specific tumor localization for diagnostic imaging and potentially for targeted radionuclide therapy.
Berat Molekul
442,4000 g/mol
LogP
-0,10
TPSA
195,00 Ų
Lipinski RO5
Lulus
Area Terapeutik
Mekanisme Kerja
Functions as a diagnostic agent by providing contrast enhancement or radioactive tracer activity that enables visualization of anatomical structures or physiological processes during medical imaging.
Pharmacokinetics (PK)
Pharmacodynamics (PD)
Functions as a diagnostic agent by providing contrast enhancement or radioactive tracer activity that enables visualization of anatomical structures or physiological processes during medical imaging.
Struktur 2D
Cite this structure
Embed this structure
SMILES
O=C(O)CC[C@H](NC(=O)N[C@@H](CCCCNC(=O)c1ccc(F)nc1)C(=O)O)C(=O)O
InChI
InChI=1S/C18H23FN4O8/c19-13-6-4-10(9-21-13)15(26)20-8-2-1-3-11(16(27)28)22-18(31)23-12(17(29)30)5-7-14(24)25/h4,6,9,11-12H,1-3,5,7-8H2,(H,20,26)(H,24,25)(H,27,28)(H,29,30)(H2,22,23,31)/t11-,12-/m0/s1
Molecular Formula
C18H23FN4O8
HBD / HBA
6 / 10
Ikatan yang Dapat Dirotasi
13
Atom Berat
31
No targets recorded
Target interaction data is not yet available for this drug.
No interactions recorded
Drug interaction data is not yet available for this compound.
No side effects recorded
Side effect data is not yet available for this drug.
Pertanyaan yang Sering Diajukan
Piflufolastat is a small molecule ligand targeting prostate-specific membrane antigen (PSMA) that is used as a radiotracer for PET imaging in prostate cancer and is under investigation for targeted radiotherapy applications in breast and pancreatic cancer. It binds with high affinity to PSMA, enabling highly specific tumor localization for diagnostic imaging and potentially for targeted radionuclide therapy.
Functions as a diagnostic agent by providing contrast enhancement or radioactive tracer activity that enables visualization of anatomical structures or physiological processes during medical imaging.
Yes, Piflufolastat is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.
References & Data Sources
- ChEMBL — European Bioinformatics Institute (EBI). CHEMBL4299851. Open-access bioactivity database.
- PubChem — National Center for Biotechnology Information (NCBI). CID 71532123. Chemical information database.
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.
Embed This Widget
Add the script tag and a data attribute to embed this widget.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<div data-drugfyi="drug" data-slug="piflufolastat"></div>Embed via iframe for maximum compatibility.
<iframe src="https://drugfyi.com/iframe/drug/piflufolastat/" width="420" height="400" frameborder="0" style="border:0;border-radius:10px;max-width:100%" loading="lazy"></iframe>Paste this URL in WordPress, Medium, or any oEmbed-compatible platform.
https://drugfyi.com/drug/piflufolastat/Add a dynamic SVG badge to your README or docs.
[](https://drugfyi.com/drug/piflufolastat/)Use the native HTML custom element.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<drugfyi-drug slug="piflufolastat"></drugfyi-drug>